Latest:
Dr. Schnabel Discusses the DCIS Recurrence Score
Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
G. Thomas Budd, MD
Latest:
Dr. Budd on Prior Trastuzumab and Paclitaxel Regimens
G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses prior treatment with trastuzumab and the effect on two regimens of paclitaxel.
Gabriel Mannis, MD
Latest:
Dr. Mannis on Targeted Agents in the Treatment of Patients With AML
Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval and potential approval of 2 new agents that will provide a more nuanced treatment approach for patients with acute myeloid leukemia (AML).
Gabriela S. Hobbs, MD
Latest:
Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Gabriela S. Hobbs, MD, Raajit K. Rampal, MD, PhD
Latest:
JAK2 Mutations and JAK Inhibitors in the Management of Myeloproliferative Neoplasms
The Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) are clonal disorders characterized by common mutations, but with distinct clinical features, treatment considerations, and prognostic outlooks.
Gagandeep Brar, MD
Latest:
Redefining BCLC B, Intermediate-Stage HCC: Is There a Role for Combination Systemic Therapy?
BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.
Gail J. Roboz, MD, Weill Cornell Medical Center
Latest:
Emerging Role of Venetoclax in the Treatment of MDS
Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.
Gal Shafirstein, DSc
Latest:
Photodynamic Therapy: Looking at Treatment of Early-Stage Oral Cancer in a New Light
Although surgery and radiotherapy are standard treatment modalities for grade T1/T2 oral cavity cancer, both approaches have well-documented limitations, including their association with adverse effects that lower quality of life for patients.